An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?
Background: Hypertriglyceridaemia, commonly found in subjects with obesity and type 2 diabetes mellitus, is associated with increased risk of coronary heart disease (CHD). Apolipoprotein C-III (apoC-III) plays an important role in regulating the metabolism of triglyceride-rich lipoproteins (TRLs) an...
| Main Authors: | , , , |
|---|---|
| Format: | Journal Article |
| Published: |
Blackwell Publishing Ltd
2008
|
| Online Access: | http://hdl.handle.net/20.500.11937/22580 |
| _version_ | 1848750909851435008 |
|---|---|
| author | Chan, D. Chen, Meifania Ooi, E. Watts, G. |
| author_facet | Chan, D. Chen, Meifania Ooi, E. Watts, G. |
| author_sort | Chan, D. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Background: Hypertriglyceridaemia, commonly found in subjects with obesity and type 2 diabetes mellitus, is associated with increased risk of coronary heart disease (CHD). Apolipoprotein C-III (apoC-III) plays an important role in regulating the metabolism of triglyceride-rich lipoproteins (TRLs) and may provide a new approach to assessing hypertriglyceridaemia. Aims: We review the role of apoC-III in regulating TRL metabolism and address the potential importance of apoC-III in clinical practice. Discussion: Hypertriglyceridaemia is chiefly a consequence of alterations in the kinetics of TRLs, including overproduction and delayed clearance of very-low density lipoprotein (VLDL). ApoC-III is an inhibitor of lipoprotein lipase and of TRLs remnant uptake by hepatic lipoprotein receptors. Elevated apoC-III, usually resulting from hepatic overproduction of VLDL apoC-III, may cause accumulation of plasma TRLs leading to hypertriglyceridaemia. The results from recent observational studies demonstrate that apoC-III is a strong predictor of risk for CHD, but this chiefly relates to apoC-III in apoB-containing lipoproteins. Lifestyle and pharmacological intervention can correct hypertriglyceridaemia by a mechanism of action that regulates apoC-III transport. Conclusions: Targeting apoC-III metabolism may therefore be an important, new therapeutic approach to managing dyslipidaemia and CHD risk in obesity, insulin resistance and type 2 diabetes mellitus. However, further work is required to establish the practical aspects of measuring apoC-III in routine laboratory service and the precise therapeutic targets for serum total apoC-III and/or apoC-III in apoB-containing lipoproteins. While showing much promise as a potentially useful cardiovascular risk factor, apoC-III is not yet ready for prime time use in clinical practice. |
| first_indexed | 2025-11-14T07:44:20Z |
| format | Journal Article |
| id | curtin-20.500.11937-22580 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T07:44:20Z |
| publishDate | 2008 |
| publisher | Blackwell Publishing Ltd |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-225802018-12-14T00:54:11Z An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor? Chan, D. Chen, Meifania Ooi, E. Watts, G. Background: Hypertriglyceridaemia, commonly found in subjects with obesity and type 2 diabetes mellitus, is associated with increased risk of coronary heart disease (CHD). Apolipoprotein C-III (apoC-III) plays an important role in regulating the metabolism of triglyceride-rich lipoproteins (TRLs) and may provide a new approach to assessing hypertriglyceridaemia. Aims: We review the role of apoC-III in regulating TRL metabolism and address the potential importance of apoC-III in clinical practice. Discussion: Hypertriglyceridaemia is chiefly a consequence of alterations in the kinetics of TRLs, including overproduction and delayed clearance of very-low density lipoprotein (VLDL). ApoC-III is an inhibitor of lipoprotein lipase and of TRLs remnant uptake by hepatic lipoprotein receptors. Elevated apoC-III, usually resulting from hepatic overproduction of VLDL apoC-III, may cause accumulation of plasma TRLs leading to hypertriglyceridaemia. The results from recent observational studies demonstrate that apoC-III is a strong predictor of risk for CHD, but this chiefly relates to apoC-III in apoB-containing lipoproteins. Lifestyle and pharmacological intervention can correct hypertriglyceridaemia by a mechanism of action that regulates apoC-III transport. Conclusions: Targeting apoC-III metabolism may therefore be an important, new therapeutic approach to managing dyslipidaemia and CHD risk in obesity, insulin resistance and type 2 diabetes mellitus. However, further work is required to establish the practical aspects of measuring apoC-III in routine laboratory service and the precise therapeutic targets for serum total apoC-III and/or apoC-III in apoB-containing lipoproteins. While showing much promise as a potentially useful cardiovascular risk factor, apoC-III is not yet ready for prime time use in clinical practice. 2008 Journal Article http://hdl.handle.net/20.500.11937/22580 10.1111/j.1742-1241.2007.01678.x Blackwell Publishing Ltd restricted |
| spellingShingle | Chan, D. Chen, Meifania Ooi, E. Watts, G. An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor? |
| title | An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor? |
| title_full | An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor? |
| title_fullStr | An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor? |
| title_full_unstemmed | An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor? |
| title_short | An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor? |
| title_sort | abc of apolipoprotein c-iii: a clinically useful new cardiovascular risk factor? |
| url | http://hdl.handle.net/20.500.11937/22580 |